Orthocell jumps as nerve repair tech shows hope for erectile dysfunction post-prostate surgery
Orthocell shares popped +10% as the company reported its flagship nerve repair product, Remplir, is being used by Australian urologists.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.